The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
=== Authorizations of COVID-19 vaccines === The COVID-19 pandemic, and sequencing of the causative virus SARS-CoV-2 at the beginning of 2020, led to the rapid development of the first approved mRNA vaccines. BioNTech and Moderna in December of the same year obtained approval for their mRNA-based COVID-19 vaccines. In December 2020, the UK Medicines and Healthcare products Regulatory Agency (MHRA) became the first global medicines regulator in history to approve an mRNA vaccine, granting emergency authorization for Pfizer–BioNTech's BNT162b2 COVID-19 vaccine for widespread use. Also, in December 2020, the US Food and Drug Administration gave emergency use authorization for the Pfizer–BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine.
Androgen receptors Calcitriol receptors Corticotropin-releasing hormone receptor 1 Corticotropin releasing hormone receptor 2 Estrogen receptors Follicle-stimulating hormone receptors Glucagon receptors Gonadotropin receptors Gonadotropin-releasing hormone receptors Growth hormone receptors Insulin receptor Luteinizing hormone Progesterone receptors Retinoid receptors Somatostatin receptors Thyroid hormone receptors Thyrotropin receptors
De novo gene birth is the process by which new genes evolve from non-coding DNA. De novo genes represent a subset of novel genes, and may be protein-coding or instead act as RNA genes. The processes that govern de novo gene birth are not well understood, although several models exist that describe possible mechanisms by which de novo gene birth may occur. Ancient de novo gene birth events are difficult to detect. Most studies of de novo genes to date have thus focused on young genes, typically taxonomically restricted genes (TRGs) that are present in a single species or lineage, including so-called orphan genes, defined as genes that lack any identifiable homolog. Not all orphan genes arise de novo, but rather through fairly well characterized mechanisms such as gene duplication (including retroposition) or horizontal gene transfer followed by sequence divergence, or by gene fission/fusion. Although de novo gene birth was once viewed as a highly unlikely occurrence, thousands of examples have now been described, and some researchers speculate that de novo gene birth could play a major role in evolutionary innovation, morphological specification, and adaptation, probably promoted by their low level of pleiotropy. Conversely, criticism of the methodology and interpretation used to identify de novo gene candidates has appeared in the literature, including arguments that some reported cases may reflect artefacts of homology detection and annotation rather than genuine novelty.
Werner discovered the spatial arrangements of the ligands that were involved in the formation of the complex hexacoordinate cobalt. His theory allows one to understand the difference between a coordinated ligand and a charge balancing ion in a compound, for example the chloride ion in the cobaltammine chlorides and to explain many of the previously inexplicable isomers. In 1911, Werner first resolved the cobalt/ammonia coordination complex hexol into optical isomers, overthrowing the theory that only carbon compounds could possess chirality.
== Production == Homoarginine is formed as a derivative from lysine through reactions similar to those of the urea cycle. Just as in the urea cycle, in its synthesis, ornithine is replaced by lysine. Ornithine transcarbamylase is the main enzyme for homoarginine synthesis. The production of homoarginine is based around the activity of this enzyme. Although ornithine transcarbamylase has a higher affinity to ornithine, it ends up catalyzing the transaminidation reaction of lysine as well, which starts homoarginine production. The reason it also catalyzes this reaction with lysine is because of the low substrate selectivity in the reaction. Another pathway for the production of Homoarginine includes glycine amidinotransferase (AGAT). This enzyme normally acts through the transfer of an amidino group from arginine to glycine, resulting in formation of guanidinoacetic acid, which is subsequently methylated by guanidinoacetate methyltransferase (GAMT) to form creatine. However, glycine amidinotransferase (AGAT) sometimes acts by using lysine instead of glycine in the reaction, therefore lysine becomes the acceptor of the amidino group, resulting in the production of homoarginine.
Sources: en.wikipedia.org
The half-life of uranium-236 is too short for it to be primordial, though it has been identified as an extinct progenitor of its alpha decay daughter, thorium-232. Uranium-236 occurs in spent nuclear fuel when neutron capture on 235U does not induce fission, or as a decay product of plutonium-240. Uranium-236 is not fertile, as three more neutron captures are required to produce fissile 239Pu, and is not itself fissile; as such, it is considered long-lived radioactive waste. Uranium-234 is a member of the uranium series and occurs in equilibrium with its progenitor, 238U; it undergoes alpha decay with a half-life of 245,500 years and decays to lead-206 through a series of relatively short-lived isotopes. Uranium-233 undergoes alpha decay with a half-life of 160,000 years and, like 235U, is fissile. It can be bred from thorium-232 via neutron bombardment, usually in a nuclear reactor; this process is known as the thorium fuel cycle. Owing to the fissility of 233U and the greater natural abundance of thorium (three times that of uranium), 233U has been investigated for use as nuclear fuel as a possible alternative to 235U and 239Pu, though is not in widespread use as of 2022. The decay chain of uranium-233 forms part of the neptunium series and ends at nearly-stable bismuth-209 (half-life 2.01×1019 years) and stable thallium-205. Uranium-232 is an alpha emitter with a half-life of 68.9 years. This isotope is produced as a byproduct in production of 233U and is considered a nuisance, as it is not fissile and decays through short-lived alpha and gamma emitters such as 208Tl.
=== Biological computers === A biological computer refers to an engineered biological system that can perform computer-like operations, which is a dominant paradigm in synthetic biology. Researchers built and characterized a variety of logic gates in a number of organisms, and demonstrated both analog and digital computation in living cells. They demonstrated that bacteria can be engineered to perform both analog and/or digital computation. In 2007, in human cells, research demonstrated a universal logic evaluator that operates in mammalian cells. Subsequently, researchers utilized this paradigm to demonstrate a proof-of-concept therapy that uses biological digital computation to detect and kill human cancer cells in 2011. In 2016, another group of researchers demonstrated that principles of computer engineering can be used to automate digital circuit design in bacterial cells. In 2017, researchers demonstrated the 'Boolean logic and arithmetic through DNA excision' (BLADE) system to engineer digital computation in human cells. In 2019, researchers implemented a perceptron in biological systems opening the way for machine learning in these systems.
Peter Benenson (born Peter James Henry Solomon; 31 July 1921 – 25 February 2005) British lawyer, writer, pamphleteer, human rights activist and the founder of human rights group Amnesty International (AI); accepted the Pride of Britain Award for Lifetime Achievement in 2001 though he later rejected and denounced Amnesty International for its criticism of Israel. Benenson was the son of British-born Harold Solomon and Russian-born Flora Benenson, grandson of Russian financier Grigori Benenson (1860–1939); served in Intelligence Corps at the Ministry of Information and worked at Bletchley Park during World War II as a cryptographer. Leila Berg (12 November 1917 – 17 April 2012) was an English children's author, editor and play specialist. She was well known as a journalist and a writer on education and children's rights. Berg was a recipient of the Eleanor Farjeon Award. John Berger, Jewish father, convert to Roman Catholicism, (5 November 1926 – 2 January 2017) English art critic, novelist, painter and poet. Berger's essay on art criticism Ways of Seeing, is known as a foundation text employing deconstruction and feminist prisms of epistemology and ontology, questioning axiomatic assumptions about gender, racial prejudice and Orientalism, whilst introducing and debating prisms of Psychological projection, Reification (Marxism), False Consciousness, Commodity fetishism, Marx's theory of alienation and essentialism. He was a supporter of the Palestinian cause, and, focused on Israel and apartheid, a member of the Support Committee of the Russell Tribunal on Palestine.
== Early life == Markin was born and raised in Lincoln, Nebraska. He received a Bachelor of Science degree in 1977 from Nebraska Wesleyan University, where he majored in chemistry with minors in mathematics and physics. He received a Ph.D. in chemistry from the University of Nebraska–Lincoln in 1980; he earned his medical degree from the University of Nebraska Medical Center (UNMC) in 1983; he completed his residency in pathology and laboratory medicine at UNMC in 1986. He has been on the UNMC faculty since 1986. His professional and academic research interests have focused on clinical laboratory automation including robotics, information systems, medical utilization management, business efficiency modeling, adult and pediatric pathology, liver/gastrointestinal pathology, telehealth, telemedicine, technology development and mobile health.
All chemical elements derive from stellar nucleosynthesis except for hydrogen and some helium and lithium. Basic chemical ingredients of life – the carbon–hydrogen molecule (CH), the carbon–hydrogen positive ion (CH+) and the carbon ion (C+) – can be produced by ultraviolet light from stars. Complex molecules, including organic molecules, form naturally both in space and on planets. Organic molecules on the early Earth could have had either terrestrial origins, with organic molecule synthesis driven by impact shocks or by other energy sources, such as ultraviolet light, redox coupling, or electrical discharges; or extraterrestrial origins (pseudo-panspermia), with organic molecules formed in interstellar dust clouds or in the solar nebula accumulating onto the planet.
Sources: en.wikipedia.org
=== Mechanism of elastic recoil === The characterization of disorder is consistent with an entropy-driven mechanism of elastic recoil. It is concluded that conformational disorder is a constitutive feature of elastin structure and function.
== Further reading == William F. Neuman and Margaret W. Neuman. (1958). The Chemical Dynamics of Bone Mineral. Chicago: The University of Chicago Press. ISBN 0-226-57512-8. Netter, Frank H. (1987). Musculoskeletal system: anatomy, physiology, and metabolic disorders. Summit, New Jersey: Ciba-Geigy Corporation ISBN 0-914168-88-6.
==== Inflammatory problems ==== High incidences of coexisting inflammatory disorders suggest a correlation between connective tissue disorders and the development of such aforementioned conditions. Inflammatory bowel diseases such as Crohn's disease, ulcerative colitis and celiac disease are more common in EDS patients when compared to control groups. Of note, patients who are already diagnosed with an inflammatory bowel disorder are not necessarily likely to develop symptoms of a connective tissue disorder, as the two have separate but not totally confounding etiologies. Eosinophilic esophagitis, an inflammatory condition characterized by allergic-type reactions to various foods and chemicals and extensive esophageal remodeling, is eight times more likely in patients with connective tissue disorders when compared to patients without.
However, there is no real demand in chemistry, physics, or engineering for isolating 234U, and the small amounts that may be wanted for research can be separated chemically from plutonium-238 that have been aged enough to accumulate its alpha decay product, which is 234U. Enriched uranium contains more 234U than natural uranium as a byproduct of the uranium enrichment process aimed at obtaining uranium-235, which concentrates lighter isotopes even more strongly than it does 235U. IAEA research paper TECDOC-1529 concludes the 234U content of enriched fuel is directly proportional to the degree of 235U—enrichment with 2% 235U resulting in 150 g 234U/ton HM (heavy metals, special meaning, relating to nuclear fuels), and the most common 4.5% 235U enrichment resulting in 400 g 234U/ton HM. The increased percentage of 234U in enriched natural uranium is not harmful to the operation of current nuclear reactors. Uranium-234 has a neutron-capture cross section of about 100 barns for thermal neutrons, and about 700 barns for its resonance integral—the average of neutrons having a range of intermediate energies. In a nuclear reactor non-fissile isotopes 234U and 238U both capture a neutron, thereby breeding fissile isotopes 235U and 239Pu, respectively. 234U is converted to 235U more easily and therefore at a greater rate than 238U is to 239Pu (via neptunium-239) because 238U has a much smaller neutron-capture cross section of just 2.7 barns.
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.